Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015; the filing does not identify the registrant as Alaunos Therapeutics, Inc. ZIOPHARM was a clinical-stage oncology company focused on synthetic immuno-oncology and cell therapies. It had no approved products and reported minimal collaboration revenue.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 / prior date |
|---|---|---|
| Revenue | $272,000 | $200,000 |
| Research and development expense | $74.249 million | $6.542 million |
| General and administrative expense | $4.250 million | $3.442 million |
| Net loss | $78.231 million | $9.711 million |
| Basic and diluted loss per share | $0.69 | $0.10 |
| Net cash used in operating activities | $9.717 million | $8.654 million |
| Cash and cash equivalents | $129.684 million at March 31 | $42.803 million at December 31, 2014 |
| Working capital | $120.1 million | $33.3 million at December 31, 2014 |
The reported R&D charge includes $67.285 million for shares issued to MD Anderson for licensed in-process research and development, a noncash item. The filing reports no debt balance; total liabilities were $11.045 million. No gross margin is presented, and margins are not meaningful given the company’s minimal revenue and development-stage operations.
Material changes versus the prior comparable period
- Net loss rose substantially, primarily reflecting the MD Anderson license charge and increased immunotherapy spending.
- Cash increased following a February public offering that generated approximately $94.3 million net. The company also issued 11.722 million shares to MD Anderson for the license and incentive consideration; outstanding shares increased to 128.233 million from 104.452 million at year-end.
- Operating cash use increased by about $1.1 million year over year. Financing activities provided $96.615 million, versus $837,000 in Q1 2014.
- Management expected existing cash, excluding the anticipated Ares-related receipt, to fund operations into Q2 2017 under current plans.
Outlook, developments and risks
- Under the March 2015 Ares Trading collaboration with Merck KGaA’s pharmaceutical business, Intrexon was due to receive a $115 million upfront payment and share half with ZIOPHARM. The company expected its $57.5 million share in Q2 2015. The agreement was subject to Hart-Scott-Rodino review and was to be accounted for in Q2.
- The MD Anderson license included three years of research funding of $15–$20 million per year. The first $3.75 million quarterly payment was made on April 13, 2015, after quarter-end.
- Management planned multiple CAR-T clinical starts and expected early data from breast cancer and glioblastoma studies in Q4 2015; these were forward-looking plans, not results. The company paused further intratumoral Ad-RTS-IL-12 development in melanoma amid changing standards and competition, while pursuing breast and brain cancer programs.
- Key risks include clinical and regulatory uncertainty, potential toxicity and manufacturing complexity of engineered cell therapies, intense competition, reliance on Intrexon and MD Anderson licenses, and the possibility that development costs or financing needs exceed expectations. The company warned it would need additional financing for longer-term plans and had no committed additional capital sources.
- The filing reports no legal matter that management considered likely to have a material adverse effect. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
- Subsequent to quarter-end, Laurence J. N. Cooper was appointed CEO on May 7, 2015.
Important facts for investors to verify
- Confirm the identity and relevance of the filing: the supplied filing is for ZIOPHARM Oncology, Inc., not Alaunos Therapeutics, Inc.
- Reconcile the R&D expense inconsistency: the financial statements report $74.249 million, while MD&A states $72.249 million. The filing text does not provide a clear reconciliation.
- Verify receipt and timing of the expected $57.5 million Ares-related payment, and the impact of agreement review and accounting treatment.
- Assess cash runway against planned clinical development and the MD Anderson research-funding commitments; management’s runway estimate depends on current plans and assumptions.
- Track clinical milestones, safety findings, regulatory requirements and future share issuance or other financing that could dilute shareholders.